Two errors occurred in this regular review by Eva Lonn and Robert McKelvie (29 April, pp 1188-92). The first sentence of the section on angiotensin converting enzyme inhibitors should read: “Angiotensin converting enzyme (ACE) inhibitors prevent the conversion of angiotensin I to angiotensin II and prevent [not cause] the degradation of bradykinin.” The penultimate sentence of the penultimate paragraph should read: “The aldosterone receptor antagonist spironolactone [not aldosterone] was recently shown to improve considerably the outcomes of patients with severe heart failure.”